Flavor enhancement as a strategy to improve food liking in cancer patients with taste and smell alterations

Autor: Drareni, K., Dougkas, A., Lusson, H., Vansteene, D., Giboreau, A., Bensafi, M.

Publikováno v: In Clinical Nutrition Open Science February 2023 47:53-63

Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.

Autor: Guigay J; Partnerships and Clinical Development - Early Assets, GORTEC, Tours, France. Electronic address: joel.guigay@gortec.fr., Ortholan C; Oncology-Radiotherapy Unit, Hospital Centre Princesse-Grace, Monaco., Vansteene D; Medical Oncology Unit, West Cancerology Institute, Saint Herblain, France., Cupissol D; Medical Oncology Unit, Cancer Institute of Montpellier, Montpellier, France., Even C; Medical Oncology Unit, Gustave-Roussy Institute, Villejuif, France., Kaminsky MC; Medical Oncology Unit, Lorraine Cancerology Institute, Nancy, France., Sire C; Oncology-Radiotherapy Unit, Hospital Group South Bretagne, Lorient, France., Blot E; Medical Oncology Unit, ELSAN Group, Private Hospital Océane, Vannes, France., Debourdeau P; Medical Oncology Unit, Sainte Catherine Institute, Avignon, France., Bozec L; Medical Oncology Unit, Curie Institute, Saint Cloud, France., Saada-Bouzid E; Medical Oncology and Research Department, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France., Fayette J; Medical Oncology Unit, Cancer Research Centre Léon Bérard, Lyon, France., Dalloz P; Medical Oncology Unit, Centre Jean Perrin, Clermont-Ferrand, France., Pointreau Y; Radiation Oncology Unit, ILC (Inter-regional Cancerology Institute) - Jean Bernard Center & Victor Hugo Private Clinic, Sarthe Cancer Center, Le Mans, France., Caer HL; Medical Oncology Unit, Hospital Centre of Saint-Brieuc, Saint-Brieuc, France., Falandry C; Medical Oncology Unit, Hospital Centre of South Lyon, Pierre Bénite, France., Digue L; Medical Oncology Unit, Saint André Universitary Hospital of Bordeaux, Bordeaux, France., Braccini A; Medical Oncology Unit, Centre Azuréen de Cancérologie, Mougins, France., Lopez S; Medical Oncology Unit, Hospital Centre of Annecy Genevois, Pringy, France., Guillet P; Medical Oncology Unit, Intercommunal Hospital Centre, La Seyne sur Mer, France., Michel C; Medical Oncology and Research Department, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France., Cheurfa N; Biostatistics and Epidemiology Unit, Gustave Roussy, Inserm U1018 Oncostat, Labelled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France., Schwob D; Biostatistics and Epidemiology Unit, Gustave Roussy, Inserm U1018 Oncostat, Labelled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France., Bourhis J; Radiotherapy Unit, Universitary Hospital Center of Vaudois, Lausanne, Switzerland., Mertens C; Oncogeriatrics Unit, Bergonié Institute, Bordeaux, France., Aupérin A; Biostatistics and Epidemiology Unit, Gustave Roussy, Inserm U1018 Oncostat, Labelled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.

Publikováno v: The lancet. Healthy longevity [Lancet Healthy Longev] 2024 Mar; Vol. 5 (3), pp. e182-e193.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Autor: Guigay, J, Auperin, A, Fayette, J, Saada-Bouzid, E, Lafond, C, Taberna, M, Geoffrois, L, Martin, L, Capitain, O, Cupissol, D, Castanie, H, Vansteene, D, Schafhausen, P, Johnson, A, Even, C, Sire, C, Duplomb, S, Evrard, C, Delord, JP, Laguerre, B, Zanetta, S, Chevassus-Clement, C, Fraslin, A, Louat, F, Sinigaglia, L, Keilholz, U, Bourhis, J, Mesia, R, Gallego, O, López Pousa A., Vazquez Fernandez, Silvia

Publikováno v: LANCET ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) showed promising results, with a median overall survival of 14.0 months in first-line recurrent or metastatic head and neck squamous-cell carcinom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a5f834e29bdb8c7182993b4ccd955297
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7939

758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial

Autor: Saint-Ghislain, M., Abdeddaim, C., Chaltiel, R., Cousin, S., Gomez-Roca, C.A., Borel, C., Ghiringhelli, F., Vansteene, D., Bigot, F., Jeannot, E., Guerini Rocco, E., Frige, G., Mazzarella, L., Francisco, M., Legrand, F., Jimenez, M., Halladjian, M., Kamal, M., Cabarrou, B., Le Tourneau, C.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S518-S518

557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial

Autor: Coutzac, C., Bigot, F., Vansteene, D., Dos Santos, M., Ghiringhelli, F., You, B., Lambert, A., Gomez-Roca, C.A., Abdeddaim, C., Neuzillet, C., Jeannot, E., Guerini Rocco, E., Frige, G., Mazzarella, L., Dupain, C., Kamal, M., Legrand, F., Jimenez, M., Filleron, T., Le Tourneau, C.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S415-S415